VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...

Cell line development plays a key role in the identification of biological targets and commercial manufacturing of biotherapeutics. Despite its importance, the process faces a number of challenges, ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Cell line development is an essential step in the manufacture of biologics: drugs derived from living organisms, such as monoclonal antibodies, recombinant proteins and vaccines. In addition to this, ...

Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and ...

RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organization, today announced a strategic partnership with BlueRock Therapeutics, a leader in stem cell therapeutic ...

Over the past decade, biologics development has moved from artisanal experimentation to a data-driven, platform-based discipline. Analytical depth has improved. Process integration has matured. Yet ...

STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to ...

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development ...